Over a year af­ter biosim­i­lars start­ed com­pet­ing, Ab­b­Vie still holds 96% of Hu­mi­ra mar­ket, re­port says

There are nine Hu­mi­ra biosim­i­lars cur­rent­ly vy­ing to de­throne the best-sell­ing drug of all-time. And so far, none of them are com­ing any­where close.

As of Feb­ru­ary, brand-name Hu­mi­ra con­trols 96% of the adal­i­mum­ab mar­ket, ac­cord­ing to the lat­est quar­ter­ly re­port from Sam­sung Bioepis. Biosim­i­lars gained just one per­cent­age point of mar­ket share since an ear­li­er ver­sion of the Sam­sung re­port re­leased six months ago, a stark re­minder that re­al com­pe­ti­tion for Ab­b­Vie’s bi­o­log­ic could take years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER